2024
Sex differences in comorbid pain and opioid use disorder: A scoping review
DeVito E, Ameral V, Sofuoglu M. Sex differences in comorbid pain and opioid use disorder: A scoping review. British Journal Of Clinical Pharmacology 2024, 90: 3067-3083. PMID: 39168150, PMCID: PMC11604518, DOI: 10.1111/bcp.16218.Peer-Reviewed Original ResearchOpioid use disorderChronic painTreatment of opioid use disorderChronic opioid usePost hoc analysisPersistent painClinical courseOpioid useComorbid painSex/gender differencesOpioid misuseOpioidPainUse disorderHighest prevalencePost-hocOutcome variablesDisordersTreatmentHuman subjectsBiological underpinningsPsychosocial factorsTreatment effectsSex differencesSex
2022
Cocaine Use Disorder (CUD): Current Clinical Perspectives
Schwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M. Cocaine Use Disorder (CUD): Current Clinical Perspectives. Substance Abuse And Rehabilitation 2022, 13: 25-46. PMID: 36093428, PMCID: PMC9451050, DOI: 10.2147/sar.s337338.Peer-Reviewed Original ResearchCocaine use disorderCo-occurring disordersUse disordersCommon co-occurring disordersCurrent clinical perspectivesSubstance use disordersCognitive behavioral therapyMedication treatmentPharmacological treatmentRisk factorsCurrent treatmentDevastating disorderLarger sample sizeTreatment planChronic effectsCocaine useBehavioral treatmentClinical perspectiveBehavioral interventionsDisordersTreatmentFuture studiesMost individualsIndividualsSample size
2021
The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes
MacLean R, Spinola S, Garcia-Vassallo G, Sofuoglu M. The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. Current Addiction Reports 2021, 8: 100-108. DOI: 10.1007/s40429-020-00352-6.Peer-Reviewed Original ResearchOpioid agonist treatmentChronic painOpioid use disorderOpioid Use Disorder Treatment OutcomesNonpharmacologic pain treatmentsIllicit opioid useDisorder treatment outcomesReviewChronic painOpioid usePain intensityPain treatmentAgonist treatmentOAT clinicsTreatment outcomesClinical carePainUse disordersDrug useRecent FindingsWeHigher likelihoodClinicOutcomesTreatmentMost studiesIntake
2020
Chapter 23 Pharmacological cognitive enhancers
Peltier M, Sofuoglu M. Chapter 23 Pharmacological cognitive enhancers. 2020, 303-320. DOI: 10.1016/b978-0-12-815298-0.00023-x.Peer-Reviewed Original ResearchSubstance use disordersSignificant health problemNovel pharmacological targetsSignificant cognitive deficitsChronic usePharmacological treatmentCandidate medicationsTreatment outcomesTreatment strategiesUse disordersHealth problemsPharmacological targetsCognitive deficitsCognitive enhancementSubstance useCognitive enhancersPotential mechanismsCognitive functioningTreatmentPharmacological cognitive enhancementPharmacological cognitive enhancersMedicationsImpairmentCocaine
2019
Pharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUD
2018
Pharmacological and Behavioral Treatment of Opioid Use Disorder
Sofuoglu M, DeVito E, Carroll K. Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research And Clinical Practice 2018, 1: 4-15. PMCID: PMC9175946, DOI: 10.1176/appi.prcp.20180006.Peer-Reviewed Original ResearchOpioid use disorderMedication-assisted treatmentSubstance use conditionsBehavioral treatmentTreatment retentionUse disordersBehavioral interventionsOpioid withdrawal symptomsFirst-line treatmentMechanism of actionOUD treatmentComorbid conditionsMedication complianceWithdrawal symptomsClinical overviewClinical guidelinesOpioid receptorsAdrenergic agonistsNonsystematic reviewDrug AdministrationKey pharmacologicalBehavioral therapyTreatment effectivenessComplex needsTreatmentThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDiseaseStimulants and Mood Disorders
MacLean R, Sofuoglu M. Stimulants and Mood Disorders. Current Addiction Reports 2018, 5: 323-329. DOI: 10.1007/s40429-018-0212-0.Peer-Reviewed Original ResearchStimulant use disorderMood disordersUse disordersSUD comorbidityClinical trialsComorbid substance use disorderRecent FindingsEpidemiological studiesCo-occurring mood disordersSubstance use disordersMethamphetamine use disorderMajority of trialsClinical outcomesPharmacological treatmentTreatment responseNeurobiological mechanismsDisordersMultiple studiesTrialsComorbiditiesPatientsDiagnosisMoodTreatmentPurposeToEpidemiology
2001
Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women
Sofuoglu M, Babb D, Hatsukami D. Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women. Pharmacology Biochemistry And Behavior 2001, 69: 299-304. PMID: 11420098, DOI: 10.1016/s0091-3057(01)00527-5.Peer-Reviewed Original ResearchConceptsEarly follicular phaseProgesterone treatmentFollicular phaseSmoking behaviorFemale smokersMenstrual cycleProgesterone levelsDose of progesteroneEffect of progesteroneSelf-administration periodMedication treatmentEndogenous estradiolExperimental sessionsExogenous progesteroneNicotine dependenceProgesteroneSubjective effectsSmokersTreatmentEstradiolSubjective responsesCigarettesSecond sessionSubjectsWomen
2000
Carvedilol affects the physiological and behavioral response to smoked cocaine in humans
Sofuoglu M, Brown S, Babb D, Pentel P, Hatsukami D. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug And Alcohol Dependence 2000, 60: 69-76. PMID: 10821991, DOI: 10.1016/s0376-8716(00)80009-5.Peer-Reviewed Original ResearchConceptsAcute treatmentPlacebo-controlled outpatient studyPhysiological effectsEffects of carvedilolDiastolic blood pressureCocaine-induced increasesNumber of cocaineCarvedilol treatmentBlood pressureOral carvedilolOutpatient studyNoradrenergic systemAdrenergic blockersCrack cocaine usersHeart rateCarvedilolBehavioral responsesCocaineCocaine usersCocaine deliveryTreatmentSubjective responsesTreatment conditionsResponseHumansEffects of Labetalol Treatment on the Physiological and Subjective Response to Smoked Cocaine
Sofuoglu M, Brown S, Babb D, Pentel P, Hatsukami D. Effects of Labetalol Treatment on the Physiological and Subjective Response to Smoked Cocaine. Pharmacology Biochemistry And Behavior 2000, 65: 255-259. PMID: 10672977, DOI: 10.1016/s0091-3057(99)00201-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressureLabetalol treatmentBlood pressureDose of labetalolEffects of labetalolSubjective responsesCocaine deliveryHeart rate increaseCocaine-induced increasesEffect of treatmentCrossover studyMedication treatmentCardiovascular responsesHeart rateAdrenergic receptorsLabetalolSmoked CocaineBehavioral effectsSubjective effectsCocaineDrug labetalolCocaine usersTreatmentDosesExperimental sessions